Proprio
- Industry
- Medical Technology
- Founded Year
- 2016
- Headquarters
- Seattle, Washington, USA
- Employee Count
- 50
Key People
- Gabriel Jones - CEO
- Samuel Browd, MD, PhD - Chief Medical Officer
- James Youngquist - CTO
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The leadership team comprises experienced professionals with over a decade in their respective fields.
Proprio's leadership includes individuals with significant experience in medical technology and business, enhancing the company's strategic direction and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: Proprio addresses a critical need for advanced surgical navigation and imaging solutions.
With the increasing complexity of surgical procedures, there is a substantial demand for technologies that improve accuracy and outcomes, which Proprio's products aim to fulfill.
- Competition
-
Aspect: Somewhat crowded
Summary: The surgical navigation market has several established players, but opportunities exist for innovation.
The market includes companies like Medtronic and Stryker; however, Proprio's integration of light field technology and AI provides a competitive edge.
- Technical Challenge
-
Aspect: Complex
Summary: Developing and integrating advanced imaging and AI technologies into surgical workflows is complex.
Creating real-time 3D visualization systems that seamlessly integrate into existing surgical practices requires overcoming substantial technical hurdles.
- Patent
-
Aspect: Strong
Summary: Proprio holds a robust patent portfolio protecting its core technologies.
A strong intellectual property position safeguards Proprio's technological advancements and supports its market position.
- Financing
-
Aspect: Well-funded
Summary: Proprio has secured significant funding, including a $43 million Series B round in July 2023.
The Series B funding round, led by prominent investors, provides the necessary capital for scaling operations and market entry.
- Regulatory
-
Aspect: Running FIH
Summary: Proprio is conducting first-in-human trials to validate its technology.
Successful first-in-human trials are critical for demonstrating safety and efficacy, paving the way for regulatory submissions.
Opportunity Rollup
- Odds of Success
- 3.6
- Peak Market Share
- 4.6
- Segment CAGR
- 10.09%
- Market Segment
- Surgical Navigation Systems
- Market Sub Segment
- Orthopedic and Neurosurgical Navigation
Year Post Launch | Market Penetration (%) |
---|---|
1 | 0.23 |
2 | 0.69 |
3 | 1.61 |
4 | 3.22 |
5 | 4.60 |
Key Takeaway
Proprio's innovative approach to surgical navigation positions it well in a growing market, though challenges in competition and technical complexity remain.